Cytomegalovirus Cell-Mediated Immunity: Ready for Routine Use?
- PMID: 38020746
- PMCID: PMC10661902
- DOI: 10.3389/ti.2023.11963
Cytomegalovirus Cell-Mediated Immunity: Ready for Routine Use?
Abstract
Utilizing assays that assess specific T-cell-mediated immunity against cytomegalovirus (CMV) holds the potential to enhance personalized strategies aimed at preventing and treating CMV in organ transplantation. This includes improved risk stratification during transplantation compared to relying solely on CMV serostatus, as well as determining the optimal duration of antiviral prophylaxis, deciding on antiviral therapy when asymptomatic replication occurs, and estimating the risk of recurrence. In this review, we initially provide an overlook of the current concepts into the immune control of CMV after transplantation. We then summarize the existent literature on the clinical experience of the use of immune monitoring in organ transplantation, with a particular interest on the outcomes of interventional trials. Current evidence indicates that cell-mediated immune assays are helpful in identifying patients at low risk for replication for whom preventive measures against CMV can be safely withheld. As more data accumulates from these and other clinical scenarios, it is foreseeable that these assays will likely become part of the routine clinical practice in organ transplantation.
Keywords: antiviral prophylaxis; cytomegalovirus management; immune monitoring; innate immunity; preventive strategies.
Copyright © 2023 Bestard, Kaminski, Couzi, Fernández-Ruiz and Manuel.
Conflict of interest statement
OB’s research is supported by a research grant network from the RICORS (Redes de Investigación Cooperativa Orientadas a Resultados en Salud) consortia by the Instituto de Salud Carlos III and co-funded by European Union (ERDF/ESF)- A way to build Europe. MF-R holds a research contract “Miguel Servet” (CP18/00073) from the Instituto de Salud Carlos III, Spanish Ministry of Science and Innovation, also co-funded by the European Union. OB, HK, LC, and OM participate in the HORUS project, which has received funding from HORIZON Europe under the grant agreement No.101057651.
Figures
Similar articles
-
Utility of Cytomegalovirus Cell-Mediated Immunity Assays in Solid Organ Transplantation.J Clin Microbiol. 2022 Aug 17;60(8):e0171621. doi: 10.1128/jcm.01716-21. Epub 2022 May 11. J Clin Microbiol. 2022. PMID: 35543099 Free PMC article. Review.
-
Viral load, CMV-specific T-cell immune response and cytomegalovirus disease in solid organ transplant recipients at higher risk for cytomegalovirus infection during preemptive therapy.Transpl Int. 2014 Oct;27(10):1060-8. doi: 10.1111/tri.12378. Epub 2014 Aug 20. Transpl Int. 2014. PMID: 24964364
-
Cytomegalovirus Cell-mediated Immunity Assays in Pediatric Transplantation.J Pediatric Infect Dis Soc. 2024 Feb 28;13(Supplement_1):S22-S30. doi: 10.1093/jpids/piae005. J Pediatric Infect Dis Soc. 2024. PMID: 38417088 Review.
-
Cellular Immunity to Predict the Risk of Cytomegalovirus Infection in Kidney Transplantation: A Prospective, Interventional, Multicenter Clinical Trial.Clin Infect Dis. 2020 Dec 3;71(9):2375-2385. doi: 10.1093/cid/ciz1209. Clin Infect Dis. 2020. PMID: 32076718 Clinical Trial.
-
CMV-Specific Cell-Mediated Immunity Predicts a High Level of CMV Replication After Prophylaxis Withdrawal in Lung Transplant Recipients.J Infect Dis. 2021 Aug 2;224(3):526-531. doi: 10.1093/infdis/jiaa727. J Infect Dis. 2021. PMID: 33245359
Cited by
-
Evaluation of T Cell Response to SARS-CoV-2 in Kidney Transplant Recipients Receiving Monoclonal Antibody Prophylaxis and the Utility of a Bivalent mRNA Vaccine Booster Dose.Microorganisms. 2024 Apr 2;12(4):722. doi: 10.3390/microorganisms12040722. Microorganisms. 2024. PMID: 38674666 Free PMC article.
-
Innate and adaptive effector immune drivers of cytomegalovirus disease in lung transplantation: a double-edged sword.Front Transplant. 2024 Jun 10;3:1388393. doi: 10.3389/frtra.2024.1388393. eCollection 2024. Front Transplant. 2024. PMID: 38993763 Free PMC article. Review.
-
Antiviral Agents for Preventing Cytomegalovirus Disease in Recipients of Hematopoietic Cell Transplantation.Viruses. 2024 Aug 8;16(8):1268. doi: 10.3390/v16081268. Viruses. 2024. PMID: 39205242 Free PMC article.
-
Recent advances in cytomegalovirus infection management in solid organ transplant recipients.Curr Opin Organ Transplant. 2024 Apr 1;29(2):131-137. doi: 10.1097/MOT.0000000000001139. Epub 2024 Jan 30. Curr Opin Organ Transplant. 2024. PMID: 38288947 Free PMC article. Review.
References
-
- Bhugra A, Khodare A, Agarwal R, Pamecha V, Gupta E. Role of Cytomegalovirus Specific Cell-Mediated Immunity in the Monitoring of Cytomegalovirus Infection Among Living Donor Liver Transplantation Adult Recipients: A Single-Center Experience. Transpl Infect Dis (2023) 25(1):e14011. 10.1111/tid.14011 - DOI - PubMed
-
- Kotton CN, Torre-Cisneros J, International CMVSF, Aguado JM, Alain S, Baldanti F, et al. Cytomegalovirus in the Transplant Setting: Where Are We Now and What Happens Next? A Report From the International CMV Symposium 2021. Transpl Infect Dis (2022) 24(6):e13977. 10.1111/tid.13977 - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials